Area of research
Pulmonary and Respiratory Medicine · Physiology
Research interest
Research interests include Cystic fibrosis, Medicine, Ivacaftor, Cystic fibrosis transmembrane conductance regulator, Internal medicine, and Placebo.
<i>Aspergillus fumigatus</i> is influenced by mucus accumulation, airway inflammation and cystic fibrosis transmembrane conductance regulator function
Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutations
Hyaluronan Ameliorates Viral Pneumonia in Mice and Humans by Inhibiting Transcription Factor E2F1
Lumacaftor inhibits channel activity of rescued F508del cystic fibrosis transmembrane conductance regulator
Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces <i>Aspergillus fumigatus</i> in Cystic Fibrosis
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor
Reduced sialylation of airway mucin impairs mucus transport by altering the biophysical properties of mucin
Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study
Engineered tRNAs suppress nonsense mutations in cells and in vivo
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one<i>F508del</i>allele: 144-week interim results from a 192-week open-label extension study
Transgenic ferret models define pulmonary ionocyte diversity and function
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis
Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection
<i>De Novo</i> Generation of Pulmonary Ionocytes from Normal and Cystic Fibrosis Human Induced Pluripotent Stem Cells
Extracellular vesicles enhance pulmonary transduction of stably associated adeno‐associated virus following intratracheal administration
The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators
Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report
COVID-19 Causes Ciliary Dysfunction as Demonstrated by Human Intranasal Micro-Optical Coherence Tomography Imaging
Potential systemic effects of acquired CFTR dysfunction in COPD
Hypoxia‐induced cystic fibrosis transmembrane conductance regulator dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis
Human distal airways contain a multipotent secretory cell that can regenerate alveoli
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI